key: cord-0753398-k8qxz2on authors: Ung, Lawson; Jonas, Jost B.; Lietman, Thomas M.; Chodosh, James title: COVID-19 and the Unfinished Agenda of VISION 2020 date: 2020-12-09 journal: Am J Ophthalmol DOI: 10.1016/j.ajo.2020.11.016 sha: 83ae31f4c0df6c6821497f7355bbe50e456d0e9a doc_id: 753398 cord_uid: k8qxz2on PURPOSE: To critically evaluate the potential impact of the coronavirus disease (COVID-19) pandemic on global ophthalmology and VISION 2020. DESIGN: Perspective supplemented with epidemiologic insights from available online databases. METHODS: We extracted data from the Global Vision Database (2017) and Global Burden of Disease Study (2017) to highlight temporal trends in global blindness since 1990, and provide a narrative overview of how COVID-19 may derail progress toward the goals of VISION 2020. RESULTS: Over 2 decades of VISION 2020 advocacy and program implementation have culminated in a universal reduction of combined age-standardized prevalence of moderate-to-severe vision impairment (MSVI) across all world regions since 1990. Between 1990 and 2017, low-income countries observed large reductions in the age-standardized prevalence per 100,000 persons of vitamin A deficiency (25,155 to 19,187), undercorrected refractive disorders (2,286 to 2,040), cataract (1,846 to 1,690), onchocerciasis (5,577 to 2,871), trachoma (506 to 159), and leprosy (36 to 26). Despite these reductions, crude projections suggest that more than 700 million persons will experience MSVI or blindness by 2050, principally owing to our growing and ageing global population. CONCLUSIONS: Despite the many resounding successes of VISION 2020, the burden of global blindness and vision impairment is set to reach historic levels in the coming years. The impact of COVID-19, while yet to be fully determined, now threatens the hard-fought gains of global ophthalmology. The postpandemic years will require renewed effort and focus on vision advocacy and expanding eye care services worldwide. RESULTS: Over 2 decades of VISION 2020 advocacy and program implementation have culminated in a universal reduction of combined age-standardized prevalence of moderate-to-severe vision impairment (MSVI) across all world regions since 1990. Between 1990 and 2017, low-income countries observed large reductions in the age-standardized prevalence per 100,000 persons of vitamin A deficiency (25, 155 to 19,187), undercorrected refractive disorders (2,286 to 2,040), cataract (1,846 to 1,690), onchocerciasis (5,577 to 2,871), trachoma (506 to 159), and leprosy (36 to 26) . Despite these reductions, crude projections suggest that more than 700 million persons will experience MSVI or blindness by 2050, principally owing to our growing and ageing global population. CONCLUSIONS: Despite the many resounding successes of VISION 2020, the burden of global blindness and vision impairment is set to reach historic levels in the coming years. The impact of COVID-19, while yet to be fully determined, now threatens the hard-fought gains of global ophthalmology. The postpandemic years will require renewed effort and focus on vision advocacy and expanding eye care services worldwide. ease (COVID-19) pandemic, more than 53 million individuals have been confirmed to be infected, resulting in more than 1.3 million deaths. 1 Healthcare systems remain besieged by local case surges, requiring a nearsingular focus within the medical and scientific community to stem the effects of ongoing disease transmission. While the direct impact of COVID-19 on healthcare has been harrowing, there are now growing concerns that the collateral damage of the current crisis will be far more diffuse and destructive to global wellbeing than first appreciated. In global public health, interruptions to initiatives that address HIV/AIDS, 2 malaria, 3 tuberculosis, 2 vaccinepreventable infections, 4 maternal and child health, 5 and the neglected tropical diseases (NTDs) 6 threaten to derail decades of progress. There are now dire projections that an additional 100 million 7 individuals will be forced into extreme poverty (earnings